AstraZeneca/Targacept's TC-5214 Will Become Decision Resources' Proprietary Clinical Gold Standard In 2013 Through 2018 For Treatment Resistant Depression

Monday, April 19, 2010 General News
Email Print This Page Comment
Font : A-A+

Surveyed U.S. and European Physicians Indicate that Effect on Depressive Symptoms is the Most Important Drug Attribute They Consider When Prescribing for the Disorder, According to a New Report from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook